Bayer Seeks Eylea Marketing Approval In EU

News: German drugmaker Bayer has submitted an application with the European Medicines Agency (EMA) for marketing authorisation of its Eylea (aflibercept) injection as a treatment of diabetic macular oedema. The drug, which was co-developed with US drugmaker Regeneron, has been approved in Europe for the treatment of patients with neovascular age-related macular degeneration. The company expects the drug to hit sales of more than EUR1bn (US$1.35bn) per year.

Bayer Seeks Eylea Marketing Approval In EU

News: German drugmaker Bayer has submitted an application with the European Medicines Agency (EMA) for marketing authorisation of its Eylea (aflibercept) injection as a treatment of diabetic macular oedema. The drug, which was co-developed with US drugmaker Regeneron, has been approved in Europe for the treatment of patients with neovascular age-related macular degeneration. The company expects the drug to hit sales of more than EUR1bn (US$1.35bn) per year.

×

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.